𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mammaglobin Gene Expression: A Superior Marker of Breast Cancer Cells in Peripheral Blood in Comparison to Epidermal-Growth-Factor Receptor and Cytokeratin-19

✍ Scribed by Grünewald, Kurt; Haun, Margot; Urbanek, Martina; Fiegl, Michael; Müller-Holzner, Elisabeth; Gunsilius, Eberhard; Dünser, Martina; Marth, Christian; Gastl, Günther


Book ID
109886288
Publisher
Nature Publishing Group
Year
2000
Tongue
English
Weight
222 KB
Volume
80
Category
Article
ISSN
0023-6837

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Over-expression of the epidermal growth
✍ Eva M. Valverius; Thierry Velu; Vidya Shankar; Fortunato Ciardiello; Nancy Kim; 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 French ⚖ 993 KB

An association exists in primary human breast tumors between high epidermal growth factor receptor (EGFR) expression and a reduced number or even absence of estrogen receptors (ER). To determine whether an increase in EGFR expression might alter the estrogen responsiveness of an ERpositive human bre

Expression of estrogen receptors in estr
✍ M. Saeed Sheikh; Zhi-Ming Shao; Jian-Chyi Chen; Xiao-Su Li; Arif Hussain; Joseph 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 1005 KB

A number of studies suggest that an inverse correlation exists between the epidermal growth factor-receptor and the estrogen receptor expression in primary human breast carcinoma as well as in established human breast carcinoma cell lines. Recent studies suggest that the epidermal growth factor-rece

Identification and characterization of a
✍ Melissa A. Wilson; Susan A. Chrysogelos 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

## Abstract The epidermal growth factor receptor (EGFR) exhibits an inverse correlation with estrogen receptor (ER) expression in the majority of breast cancers, predicting a poor response to endocrine therapy and poor survival rate. Inappropriate overexpression of EGFR in breast cancer is associat

Epidermal growth factor receptor immunoh
✍ Fred R. Hirsch; Rafal Dziadziuszko; Nick Thatcher; Helen Mann; Claire Watkins; D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## BACKGROUND The ISEL (Iressa Survival Evaluation in Lung Cancer) clinical trial evaluated the efficacy of gefitinib versus placebo in pretreated nonsmall‐cell lung cancer patients. Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR)